Literature DB >> 17456052

The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target.

Jan A Burger1, Andrea Bürkle.   

Abstract

Chemokine (C-X-C motif) receptor 4 (CXCR4) is essential for homing and maintenance of haematopoietic stem cells in distinct stromal cell niches within the marrow. Chemotactic responsiveness of haematopoietic stem cells is restricted to the ligand for CXCR4, stromal cell-derived factor-1 (SDF-1/CXCL12), which is constitutively secreted by marrow stromal cells. Myeloid and lymphoid leukaemia cells also express CXCR4 that induces leukaemia cell chemotaxis and migration beneath marrow stromal cells. CXCR4 expression levels have a major prognostic impact in acute myeloid leukaemia. There is growing in vitro and in vivo evidence that CXCR4 expression by leukaemia cells allows for homing and their retention within the marrow. As such, leukaemia cells appear to utilise CXCR4 to access niches that are normally restricted to progenitor cells, and thereby reside in a microenvironment that favours their growth and survival. CXCR4- and integrin-mediated contact between leukaemia cells and stromal cells protects leukaemia cells from spontaneous and chemotherapy-induced cell death and therefore may represent a mechanism to explain minimal residual disease and subsequent relapses commonly seen in the treatment of these diseases. This review summarises our current knowledge regarding the importance of CXCR4 in acute and chronic leukaemia, discusses the importance of CXCR4 detection by flow cytometry in the diagnostic workup of leukaemia patients, and introduces the potential role of CXCR4-targeting compounds for the treatment of leukaemia patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17456052     DOI: 10.1111/j.1365-2141.2007.06590.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  52 in total

1.  Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.

Authors:  Kira Orlovsky; Alexander Kalinkovich; Tanya Rozovskaia; Elias Shezen; Tomer Itkin; Hansjuerg Alder; Hatice Gulcin Ozer; Letizia Carramusa; Abraham Avigdor; Stefano Volinia; Arthur Buchberg; Alex Mazo; Orit Kollet; Corey Largman; Carlo M Croce; Tatsuya Nakamura; Tsvee Lapidot; Eli Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

2.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

Review 3.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

4.  Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy.

Authors:  Benjamin Boyerinas; Maya Zafrir; Ali E Yesilkanal; Trevor T Price; Elizabeth M Hyjek; Dorothy A Sipkins
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

5.  QTL analyses of lineage-negative mouse bone marrow cells labeled with Sca-1 and c-Kit.

Authors:  Mays Jawad; Clare Cole; Abigail Zanker; George Giotopoulos; Simon Fitch; Christopher J Talbot; Mark Plumb
Journal:  Mamm Genome       Date:  2008-02-21       Impact factor: 2.957

6.  64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Authors:  Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter
Journal:  Bioorg Med Chem       Date:  2009-01-15       Impact factor: 3.641

7.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

8.  Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.

Authors:  Federica Barbieri; Adriana Bajetto; Tullio Florio
Journal:  J Oncol       Date:  2009-12-14       Impact factor: 4.375

9.  Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.

Authors:  Morgan O'Hayre; Catherina L Salanga; Thomas J Kipps; Davorka Messmer; Pieter C Dorrestein; Tracy M Handel
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

10.  Inhibition of gluconeogenesis in primary hepatocytes by stromal cell-derived factor-1 (SDF-1) through a c-Src/Akt-dependent signaling pathway.

Authors:  Hui-Yu Liu; Ge-Bo Wen; Jianmin Han; Tao Hong; Degen Zhuo; Zhenqi Liu; Wenhong Cao
Journal:  J Biol Chem       Date:  2008-09-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.